Mumbai: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Omeprazole Delayed-Release capsules 40 mg from the United States Food and Drugs Administration (FDA) to market a generic version of AstraZeneca Pharmaceuticals LP (AstraZeneca) Prilosec® Delayed-Release capsules 40mg.

Lupin’s Omeprazole Delayed-Release capsules 40 mg are the AB rated generic equivalent of AstraZeneca’s Prilosec® Delayed-Release capsules 40mg. It is indicated for the short-term treatment of Duodenal Ulcer, Gastric Ulcer, treatment of Gastro Esophageal Reflux Disease (GERD), maintenance of healing of Erosive Esophagitis and Pathological Hypersecretory conditions.

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also amongst the top 10 generic pharmaceutical players in Japan and South Africa (IMS). For the financial year ended 31st March 2015, Lupin’s Consolidated turnover and Profit after Tax were 125,997 million (USD 2.06 billion) and 24,032 million (USD 393 million) respectively. Please visit http://www.lupin.com for more information.

About Aenova Group

The Aenova Group is one of the world’s largest providers of services covering the entire value chain for the development and production of all the main dosage forms and product groups in the field of medicines and dietary supplements. As the European business-to-business market leader, the Aenova Group focuses on high standards of quality, innovative technologies and a clear vision for the future. The group operates overall 29 locations in eleven countries and employs more than 4700 people.

You could also follow us on Twitter – www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai – 400 098.

For further information or queries please contact –

Shamsher Gorawara
Head – Corporate Communications
Ph: +91-98 20 338 555
Email: shamshergorawara@lupin.com

Or

Alpesh Dalal
Head – M & A and Investor Relations
Lupin Limited
Ph: +91 98 20 023 511
Email: alpeshdalal@lupin.com

Safe Harbor Statement